Have superbugs breached the last line of antibiotic defences for the first time? Industry gathers next March to collaborate on tackling antimicrobial resistance

With a focus on pushing financial and collaborative incentives to accelerate clinical success of antibiotic drugs, the agenda for SMi’s 18th annual summit on Superbugs & Superdrugs will spotlight on models for successful partnerships, progressive R&D, strengthening the antibiotic pipeline and pioneering approaches to "smart" antibiotics.

The timely event follows on from recent news confirming that superbugs resistant to all antibiotics, have spread to Europe for the first time after it was revealed a patient in Denmark has become infected with an untreatable form of salmonella. Experts fear it is the start of a global epidemic of untreatable infections.*

* Source: http://m.nzherald.co.nz/lifestyle/news/article.cfm?c_id=6&objectid=11556763

The advisory board for SMi's 18th annual Conference "Superbugs & Superdugs" said: "To combat potential epidemic requires both industry and government collaboration on an international level in antibiotics R&D investments, preventive measures and emergency response"

The programme for the established industry gathering will provide 12 insights into tackling antimicrobial resistance (AMR).

1. Transcrip Partners open the conference discussing what needs to be done NOW
2. BARDA provide guidance on funding opportunities and address goals in the US National Plan to combat AMR
3. The role of touch surfaces in the acquisition of infection and spread of AMR explained by ACT Surfaces Ltd
4. New in vitro models to understand drug resistance at the tissue site of infection presented by Karolinksa Institutet
5. Puiblic Health England investigate outbreaks using whole genome sequencing as a gold standard approach for molecule strain typing
6. QuantuMDx Group optimise speed and accuracy for rapid detection
7. Chemical Biology Ventures review the alternatives to antibiotics
8. Spero Therapeutics develop NCE's and combination methods that successfully penetrate the outer bacterial membrane
9. Da Volterra discuss clinical development of broad-spectrum anti-infective treatment drugs
10. Antimicrobial peptides explored by Cantab Anti-Infectives
11. UNT Health Science Center's Director, William Weiss, looks at the rationale for combination therapy
12. TNO analyse AMR development through metagenomics and look ahead into the next generation of sequencing.
    
    

This is just a snapshot of what will be included on the agenda for Superbugs & Superdrugs 2016. Further information including the full speaker line-up and detailed itinerary is available online.

Find out more

About SMi

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk